KORU Medical Systems (NASDAQ:KRMD) reported preliminary 2025 revenue that exceeded the high end of its guidance on Monday, as the medical technology firm prepares to pivot from its core immunology business into the high-growth oncology market.
The Mahwah, New Jersey-based company expects full-year 2025 revenue of $41.1 million, a 22% increase over the prior year.
The performance was capped by a strong fourth quarter, where revenue grew 23% to $10.9 million.
Notably, KORU achieved a significant financial milestone by generating positive cash flow from operations for the full year, ending December with a cash balance of $8.9 million.
The company plans to release its formal 2026 guidance in March.
Management has previously indicated that it expects to sustain revenue growth in the 20% range as it scales its international presence and moves into new therapeutic areas beyond immunoglobulin.